Bionomics Limited (ASX: BNO) a global clinical stage biopharmaceutical company, has accepted an offer from Domain Therapeutics to sell its two wholly owned subsidiaries, PC SAS and Neurofit SAS.
- Bionomics has an intercompany debt of €1.8 million, which is owed to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates;
- This debt will be taken by Domain after the acquisition of the companies.
At AEST 01:13PM the stock was trading at $0.085 per share, down by 5.556% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.